We identified pregnenolone and irinotecan as compounds that can upregulate ORM1 and OVGP1, respectively, and showed that these agents inhibit MM cell viability in vitro, while restoring the expression of their target proteins. The gene discussed is OVGP1; the disease is Miyoshi myopathy.